Amenable epigenetic traits of dental pulp stem cells underlie high capability of xeno-free episomal reprogramming by Chandrabose, S.T. et al.
RESEARCH Open Access
Amenable epigenetic traits of dental pulp
stem cells underlie high capability of xeno-
free episomal reprogramming
Srijaya Thekkeparambil Chandrabose1†, Sandhya Sriram2†, Subha Subramanian2, Shanshan Cheng3,
Wee Kiat Ong2,4, Steve Rozen3, Noor Hayaty Abu Kasim1* and Shigeki Sugii2,5*
Abstract
Background: While a shift towards non-viral and animal component-free methods of generating induced pluripotent
stem (iPS) cells is preferred for safer clinical applications, there is still a shortage of reliable cell sources and protocols for
efficient reprogramming.
Methods: Here, we show a robust episomal and xeno-free reprogramming strategy for human iPS generation from
dental pulp stem cells (DPSCs) which renders good efficiency (0.19%) over a short time frame (13–18 days).
Results: The robustness of DPSCs as starting cells for iPS induction is found due to their exceptional inherent stemness
properties, developmental origin from neural crest cells, specification for tissue commitment, and differentiation capability.
To investigate the epigenetic basis for the high reprogramming efficiency of DPSCs, we performed genome-wide DNA
methylation analysis and found that the epigenetic signature of DPSCs associated with pluripotent, developmental, and
ecto-mesenchymal genes is relatively close to that of iPS and embryonic stem (ES) cells. Among these genes, it is found
that overexpression of PAX9 and knockdown of HERV-FRD improved the efficiencies of iPS generation.
Conclusion: In conclusion, our study provides underlying epigenetic mechanisms that establish a robust platform for
efficient generation of iPS cells from DPSCs, facilitating industrial and clinical use of iPS technology for therapeutic needs.
Keywords: Induced pluripotent stem cells, Dental pulp-derived mesenchymal stem cells, Stem cell therapeutics,
Regenerative medicine, Xeno-free, Feeder-free, Episomal vector reprogramming
Background
The capability of human pluripotent stem cells to differ-
entiate toward multilineage adult tissues provides ample
cellular sources for cell therapy. Shinya Yamanaka and his
group made the landmark discovery of reprogramming
somatic cells by introducing transcription factors chosen
from embryonic stem (ES) cells and transforming them
into induced pluripotent stem (iPS) cells [1]. This exciting
discovery paved the way for replacing the use of ethically
and politically controversial ES cells in cell therapies. In
vitro modelling of patients’ own cells mimicking human
diseases became possible for studying the nature and com-
plexity of genetic diseases and for application in drug dis-
covery [2]. iPS technology can be used for elucidating the
complexity of many human ailments, especially regarding
genetic, degenerative, injured or age-associated conditions
related to neurological systems, hepatic, cardiac, vision,
bone disorders, wounding, autoimmune diseases, spinal
cord injury, metabolic disorders, and certain types of
cancers [3–5].
The initial attempts to induce reprogramming were
undertaken with viral-mediated vectors for expressing
the transcription factors; however, with time, multiple ef-
forts were made to improve the reprogramming strat-
egies to increase the efficiency of iPS generation and
also to adhere to cell therapy practices. Attempts include
improving the reprogramming strategies using synthetic
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mRNAs, synthetic miRNAs, recombinant proteins,
temperature-sensitive Sendai virus, and episomal plas-
mids [6, 7]. Currently, standard iPS culture systems are
innately unstable and difficult for application in clinical
therapies due to the presence of various xenogenic factors,
such as feeder layers, growth factors, and extracellular
matrix (ECM) components in culture media, which makes
the quality control of cells difficult. Consequently, to im-
prove the clinical utility of iPS cells, attempts were made
to use feeder layers, serum, or ECM of human origin for
supporting the iPS culture in a physiological niche [8–10].
However, the complication of limited sources of human
materials and their laborious maintenance efforts ham-
pered the possibility of testing these cells in human clin-
ical trials. Hence, to facilitate the implementation of iPS
cell-based therapies, xeno-free and feeder-free alternative
materials and methods minimizing human materials were
developed, but this development has been relatively slow
due to the lower efficiency of reprogramming in most of
the cell types tested [8, 11].
Significant efforts have been made at looking for an ideal
starting cell population for reprogramming [12]. It is gen-
erally better to have more developmentally immature cells
as the starting source as they exhibit inherently higher pro-
liferation, differentiation, and regenerative properties. This
reduces the risk of mutations, chromosomal damage, or
accumulated epigenetic changes compared to older cells
[7]. We chose dental pulp stem cells (DPSCs) as the start-
ing material in our experiments as they are known for
their outstanding biological characteristics [13]. DPSCs are
immature mesenchymal stem cells (MSCs) placed in the
same lineage of cells as the umbilical cord- and Wharton’s
Jelly-derived stem cells [14]. DPSCs are a rich source of
potent MSCs despite the small amount of tissue samples
obtained [15]. They are highly multipotent, have immuno-
modulatory properties, and can be obtained relatively eas-
ily by tooth extraction procedures [16–19]. The isolation
procedure of the DPSCs is simple and robust. Remarkably,
DPSCs also support reprogramming and induction of plur-
ipotency in a more refined manner, possibly due to their
dual mesectodermal and neural crest origins and inherent
expression of pluripotent factors including Oct-4, Nanog,
c-Myc, Sox2, stage-specific embryonic antigens (SSEA-3,
SSEA-4), and tumour recognition antigens (TRA-1-60 and
TRA-1-81) [15, 17, 20, 21]. Altogether, these factors pro-
vide a compelling reason to use DPSCs for establishing a
robust iPS reprogramming protocol.
In this manuscript, we report a clinically applicable
method to efficiently derive human iPS cells from
DPSCs using episomal vector transduction and culturing
in xeno-free media. We compare reprogramming of
DPSCs with that of adipose-derived stem cells (ASCs)
which were previously shown to be superior to most
other cell types in reprogramming efficiency and feeder
independence [22]. The amenable propensity for repro-
gramming is at least explained by the characteristic epi-
genetic signatures of DPSCs, which show overlap in DNA
methylation levels with iPS cells in a number of pluripo-
tent, developmental, and mesenchymal gene loci. Among
these, at least two genes, PAX9 and HERV-FRD, appear to
affect reprogramming since overexpression of PAX9 and
knockdown of HERV-FRD result in improvement in iPS
generation efficiencies.
Methods
Isolation of primary DPSCs and cell culture
To derive human DPSCs, intact human teeth were col-
lected with informed consent from patients undergoing ex-
traction at the Faculty of Dentistry, University of Malaya,
Malaysia. Under sterile conditions, the root surfaces of the
teeth were cleaned with povidone-iodine (Sigma-Aldrich,
St. Louis, MO, USA) and the pulp was extracted within 2 h
post-extraction. Thereafter, the tissues were kept in a
1.5-ml tube in 1× knockout Dulbecco’s modified Eagle’s
medium (KO-DMEM; Invitrogen), 10% fetal bovine
serum (FBS; Hyclone), 2% penicillin/streptomycin (P/S;
Invitrogen), 5% Glutamax (Invitrogen), 100 μg/ml ascorbic
acid (Sigma-Aldrich), and 1× insulin-transferrin-selenium
(ITS; Invitrogen) and transported to the laboratory for iso-
lation of the cells. The pulp tissue was minced into small
fragments prior to digestion in a solution of 3 mg/ml colla-
genase type I (Gibco) for 40 min at 37 °C. After neutralisa-
tion with 10% FBS, the cells were centrifuged, seeded in a
T25 culture flask (BD Biosciences) with culture medium
containing KO-DMEM, 10% FBS, 1× P/S, and 1%
Glutamax, and incubated in humidified atmosphere of 5%
CO2 at 37 °C. Non-adherent cells were removed 48 h after
initial plating. The medium was replaced every 3 days until
the cells reached 80–90% confluency. The DPSCs were fur-
ther passaged and frozen down in Bambanker (Lymphotec)
and stored in liquid nitrogen for future use.
The list of commercial (Lonza and Allcells) and
patient-derived dental cells used in this manuscript can
be found in Additional file 1: Table S1. DPSCs were
grown in vitro in Poietics™ DPSC BulletKit medium
(Lonza) according to the manufacturer’s instructions.
ASCs were cultured in DMEM containing 15% FBS,
non-essential amino acids (NEAA; 1%), basic fibroblast
growth factor (bFGF; 5 ng/ml) and P/S as previously de-
scribed [9, 23, 24]. Upon reaching cell confluency of
80–90%, cells were detached using TrypLE Express and
split according to the experimental requirements. Media
change for the cells was performed every 2–3 days. For
xeno-free culture of DPSC lines, StemPro MSC SFM
Xenofree (Lonza) was used from a very early passage
(passage 2). DPSC proliferation was slower in xeno-free
media when compared to normal media, consistent with
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earlier reports [25, 26]. All cells were cultured in a
humidified incubator at 37 °C in 5% CO2.
Flow cytometric analysis
Flow cytometric analysis for MSC surface markers was
performed for both normal and xeno-free conditioned
DPSCs. Cultured DPSCs were trypsinized and a total of
2 × 105 cells were suspended in staining buffer (DMEM
without phenol red with 2% FBS) as described previously
[23]. Cells were then stained directly with fluorochrome-
conjugated antibodies and incubated on ice for 30 min.
Antibodies used were CD31_FITC, CD105_Alexa Fluor
647-A, CD73_FITC, CD14_Alexa Fluor 647-A,
CD90_FITC, and CD45_Alexa Fluor 647-A (all provided
by BD Biosciences). After staining, cells were washed
and suspended in sorting buffer before analysis by flow
cytometry (LSR II, BD Biosciences).
Culture of human ES and iPS cells
The human ES cell line (H1) was obtained from WiCell
Research Institute and cultured on Matrigel (Corning)
or MEF feeder cells (GlobalStem) in hES medium as de-
scribed previously [9]. H1 hES cell line and established
iPS cell lines were maintained in either of the following
combinations: MEF feeders with hES medium (DMEM/
F12 supplemented with 20% knock-out serum replacement
(Invitrogen), 1 mM Glutamax, 1 mM NEAA (Invitrogen),
P/S, 0.1 mM β-mercaptoethanol (Millipore), and 10 ng/ml
b-FGF for feeder-dependent culture; Matrigel-coated plates
with hES cell qualified mTeSR1 (Stemcell Technologies)
for feeder-free culture; or CELLstart (Life Technologies)-
coated plates with NutriStem medium (Stemgent) for
xeno-free, feeder-free culture. Fresh medium change was
performed every day and cells were passaged 1:3–1:5 using
dispase (Stemcell Technologies) or collagenase IV
(Stemcell Technologies). Detailed methods for human
pluripotent stem cell passaging have been described previ-
ously [9]. Human iPS cell lines from ASCs were established
as previously described [9, 22].
Viral-based iPS reprogramming protocol
Yamanaka’s pMX-based retroviral vectors were from
Addgene (# 17217, 17218, 17219, and 17220 for human
Oct4, Sox2, Klf4, and c-Myc) [1]. To estimate transduction
efficiencies, pMX-based green fluorescent protein (GFP)
vector (Cell Biolabs) was used [9, 27]. These plasmids
were transfected into the 293 T packaging cell line that in-
corporated gag/pol packaging, and VSV-G envelope plas-
mids (Addgene # 8449 and 8454) to generate high titre
retroviruses as previously described [9]. Forty-eight hours
post-transfection, viral supernatant was collected and fil-
tered with 0.45-μm syringe filters, and 1 × 106 cells were
seeded in a 10-cm culture dish. The following day, cells
were transduced with viral supernatants with equal
volume of each factor supplemented with 8 μg/ml
polybrene (Sigma-Aldrich) and incubated overnight. The
following day, fresh expansion media were added to the
cells. The next day, cells were harvested with TrypLE
Express, and transferred to a 10-cm dish that had been
seeded with either feeder (MEF) or feeder-free (Matrigel)
based culture conditions. The following day, medium was
changed with hES or mTESR1 cell culture medium. The
reprogramming efficiency was calculated as the
percentage of iPS colony number per number of
GFP-positive cells.
Episomal-based iPS reprogramming protocol
Episomal plasmids developed by Yamanaka’s lab were
obtained from Addgene: pCXLEhOct3/4-shp53-F
(Addgene # 27077), pCXLE-hSK (Addgene # 27078),
pCXLE-hUL (Addgene # 27080), and pCXLE-EGFP
(Addgene # 27082) [28]. Cells (1 × 106) were harvested
using TrypLE and the cell pellet was washed once in 1×
phosphate-buffered saline (PBS). The cells were then re-
suspended in Nucleofector solution supplied in the
Nucleofector kit R (Lonza), and 1 μg of each plasmid
was added to the cell suspensions for each reaction as
recommended by the manufacturer. Next, cell suspen-
sions were transfected with the Program FF-113 on a
Nucleofector 2b Device. After 10 min of incubation, the
transfected cells were re-suspended in respective MSC
culture medium (either DPSCGM or StemPro MSC
SFM Xenofree) in 10-cm culture dishes. Early passage
MSCs in the growth phase (less than passage 5) were
used for all experiments. The reprogramming efficiency
was calculated as the percentage of iPS colony number
per number of EGFP-positive cells.
For both sets of reprogramming experiments (using
viral and episomal vectors) further enrichment was carried
out using small molecules to improve the reprogramming
process and improve iPS generation quality [6]. Starting
from the next day of transfection, daily media change of
respective MSC culture medium was performed which
was supplemented with 0.5 mM sodium butyrate
(Sigma-Aldrich). On day 7 post-transfection, 1 × 105 vi-
able cells were seeded over MEF feeders for feeder-based
iPS derivation; 2 × 105 viable cells were seeded for feeder-
free iPS derivation into one well of a six-well plate, which
was either pre-coated with Matrigel or CELLstart (for the
xeno-free condition). The following day, MSC medium
was changed to hES medium (feeder layer) or mTeSR1
(feeder-free) or NutriStem (xeno-free), supplemented with
0.5 mM sodium butyrate. At 12 days post-transfection,
supplementation of sodium butyrate was stopped, and
conditioned further with SMC4 cocktail (consisting of
small molecules of PD0325901, CHIR99021, Thiazovivin
and SB431542 (FOCUS Biomolecules)) in hES medium/
mTeSR1/NutriStem. This media supplement was
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continued until initial colony formation began, usually be-
tween 13 and 17 days post-transfection. When iPS colony
formation was observed, the SMC4 addition was stopped
and only hES/mTeSR1/NutriStem medium was used to
culture and further passage the colonies.
Over-expression and knock-down and of PAX9 and
HERV-FRD
For the over-expression study, DPSCs (L1) were nucleo-
fected simultaneously using episomal reprogramming fac-
tors as mentioned above along with the PCMV6-AC-GFP
vector expressing human PAX9 (OriGene cat. #
PS100019) for over-expression of PAX9. As the control,
the empty vector pCMV6-AN-GFP was used. For the
knock-down study, DPSCs (L1) were initially nucleofected
using episomal reprogramming factors as mentioned
above, and then incubated for a period of 10 min. This
was followed by the addition of small-interfering (si)RNA
against human ERVFRD-1 (ON-TARGET plus; GE
Dharmcon) for transient silencing of HERV-FRD during
reprogramming. The siRNA control was the vehicle alone.
Both groups of nucleofected cells were then used for the
downstream procedure as discussed previously in our
methods.
Immunofluorescence live cell staining
Reprogrammed cells were immune-stained with fluores-
cent live cell stain TRA-1-60 (R&D Systems, GloLIVE
NL557), TRA-1-81 (MACS Miltenyi Biotec), and alkaline
phosphatase (Life Technologies) as per the manufac-
turers’ instructions. After incubating with the live stain-
ing antibodies, cells were washed three times with PBS
and images were immediately captured using a Nikon
microscope TS100 and ImageXpress Micro High
Content Image System.
Gene expression analysis
Total RNA was isolated from cells in TRIzol reagent
(Invitrogen), and purified using the RNA easy kit
Column (Qiagen) as per the manufacturer’s instruction.
Complementary DNA (cDNA) was synthesised from
purified RNA using the RevertAid H minus first strand
cDNA synthesis kit (Fermentas). Quantitative polymer-
ase chain reaction (qPCR) was subsequently carried out
using SYBR Green PCR Master Mix on a StepOnePlus
Real-Time PCR System (Applied Biosystems). Primer se-
quences used in the current study are listed in Table 1.
cDNA from the H1 hES cell line was used as a control
for the hiPS lines. Samples were run in triplicates and
their relative mRNA expression was calculated using the
ΔΔct method and normalised to GAPDH.
Karyotyping
Actively dividing human ES and iPS cells were cultured in
25-cm2 culture flasks. Upon reaching 70–80% confluency,
cell cultures were transported at room temperature to the
Cytogenetics Laboratory. Karyotyping analysis was
performed by the Cytogenetics Laboratory from the
Department of Pathology and Laboratory Medicine, at KK
Women’s and Children’s Hospital, Singapore.
In vitro differentiation analysis
For spontaneous in vitro differentiation, DPSC-derived
iPS (DiPS) cells were grown to confluency and passaged
by dispase. Cells were resuspended in hES medium
(without bFGF) and transferred to low-attachment six-
well plates (Greiner Bio One). Medium change was
made every 3 days. Embryoid bodies (EBs) were formed
[29]; day 8–10 EBs were transferred to a 12-well plate pre-
coated with 0.1% gelatin and cultured for a further 12
days. Subsequently, the attached EBs were allowed to
undergo spontaneous differentiation. These differentiated
cells were later stained with three germ layer immuno-
cytochemistry antibodies (Life Technologies) as per the
manufacturer’s instructions.
In vivo differentiation analysis
For in vivo pluripotency determination, a teratoma forma-
tion assay was performed. DiPS cells were grown to con-
fluency and passaged by dispase. Approximately 2–5 ×
106 cells (one confluent well of a six-well plate) was used
per animal. Cell pellets were resuspended in a mixture of
50% Matrigel and 50% mTeSR1, and 150 μl of the iPS cell
suspension was injected into the subcutaneous area above
the thigh (quadriceps) muscle of 6- to 8-week-old NOD-
SCID mice under isoflurane anaesthesia with isoflurane.
After 8–10 weeks, when a teratoma developed, animals
were sacrificed by carbon dioxide asphyxiation, and the
teratomas were excised and fixed in 4% paraformaldehyde,
prepared for paraffin sections, and stained for haematoxy-
lin and eosin (H&E). Histological processing and H&E
staining were performed by the Advanced Molecular
Pathology Laboratory from the Institute of Molecular and
Cell Biology, Singapore.
DNA methylation analysis
ASC-derived iPS (AiPS) and DiPS cells were used. Genomic
DNA from AiPS/DiPS and from their corresponding mes-
enchymal starting cell populations was extracted from ap-
proximately 1 × 106 cells using a QIAamp DNA Mini Kit
(Qiagen) as per the manufacturer’s instructions.
Approximately 1 μg genomic DNA of each sample was
bisulphite converted and subsequently processed for profil-
ing with the Illumina Infinium DNA methylation platform
(HumanMethylation450 BeadChip) at the Genome Biology
Facility at Duke-NUS Medical School, Singapore. The
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methylation data were subject to quality control and proc-
essed in R using the Minfi package (version: 1.18.2) [30], re-
moving probes with a detection p value greater than 0.05 in
more than 25% of all samples, probes which contain com-
mon single nucleotide polymorphisms (SNPs), and probes
on the sex chromosomes. Differential methylation analysis
based on M values was performed using two-way analysis
of variance (ANOVA), controlling for matched sample
sources and correcting for multiple testing using the
Benjamini-Hochberg method. In addition, ingenuity path-
way analysis (IPA) was also performed to analyse the set of
genes that undergo significant epigenetic changes while
transforming from the somatic cell state into the iPS cell
state.
Neural progenitor cell generation
Neural progenitor cells (NPCs) were generated from DiPS
cells and H1 cells using STEMdiff™ Neural Induction
Medium (Stemcell Technologies) using an EB-based
protocol as per the manufacturer’s instructions.
Statistical analysis
Data are expressed as mean ± standard deviation (SD),
unless otherwise stated. All experimental assays were
performed in triplicates. For differential methylation
analysis, M values were determined using two-way
ANOVA and corrected for multiple testing using the
Benjamini-Hochberg method.
Results
Reprogramming of DPSCs using viral and episomal
methods
The conventional standard reprogramming protocol
(using Yamanka’s viral plasmids of OCT4, SOX2, KLF4,
and C-MYC) was performed initially to ascertain the re-
programming threshold of DPSCs that could be achieved
in our laboratory. This four-factor retroviral transduction
method yielded approximately 0.02% (feeder-free) to
0.05% (feeder) efficiency in terms of iPS colonies, and ap-
proximately 80–90 colonies in one well of a six-well
culture plate when counted at post-transduction days
(d)20–30. The number of transduced cells was assessed by
a GFP-encoding retroviral vector, as shown in Additional
file 1: Figure S1a, which was estimated to be 85–90%
based on cell count. Several DPSC-derived iPS (DiPS) cell
lines generated using the retrovirus method were estab-
lished, but only one line (L1_viral) was used as a standard
for further downstream characterisation.
In parallel, experiments were conducted using episomal
vectors which contained the transcription factors OCT4,
SOX2, KLF4, L-MYC, LIN28, and shTP53 (knock-down of
p53) [28]. These constructs are non-viral and non-
integrative, and oncogenic C-MYC was replaced with
non-oncogenic L-MYC, assuring more safety while main-
taining reprogramming efficiency. The episomal repro-
gramming method resulted in a lesser transfection
efficiency of about 20–30% only, as shown in Additional
file 1: Figure S1b, c, based on GFP-positive cells. The re-
programming efficiency in DPSCs using episomal vectors
was 0.05% in the feeder-free condition. Other human cell
types, such as ASCs, were reported to inherently enable
feeder-free reprogramming. Surprisingly, the reprogram-
ming efficiency of DPSCs under feeder-free conditions
was comparatively higher than that of ASC-derived iPS
colonies, which was approximately 0.008% [22, 31].
Improvement of iPS colony formation time and efficiency
using SMC4 cocktail
To improve the reprogramming efficiency of DPSCs fur-
ther, we supplemented the reprogramming media with
small molecules (“SMC4 cocktail”) during feeder and
feeder-free reprogramming using both viral transduction
(control) and episomal transfection. SMC4 consists of
inhibitors for transforming growth factor (TGF)β, MEK,
Table 1 Primer sequences used for quantitative polymerase chain reaction analysis
Gene Forward 5’ to 3’ Reverse 5’ to 3’
GAPDH CAAGGTCATCCATGACAACTTTG GGCCATCCACAGTCTTCTGG
ACTA CTCGGAGATCATCACGTTTG CCTTGGAAATCTCGAAGTGC
LIN28 GAAGCGCAGATCAAAAGGAG GCTGATGCTCTGGCAGAAGT
OCT4 GCAAAACCCGGAGGAGTC CCACATCGGCCTGTGTATATC
SOX2 TTGCTGCCTCTTTAAGACTAGGA CTGGGGCTCAAACTTCTCTC
NANOG CCAACATCCTGAACCTCAGC GCTATTCTTCGGCCAGTTG
DPPA2 TGGTGTCAACAACTCGGTTTG CTCGAACATCGCTGTAATCTGG
TGFb1 GCAGCACGTGGAGCTGTA CAGCCGGTTGCTGAGGTA
PDGFRA AGGTGGTTGACCTTCAATGG TTTGATTTCTTCCAGCATTGTG
FN1 CTGGCCGAAAATACATTGTAAA CCACAGTCGGGTCAGGAG
hERVFRD TGAGGAGGGCAATCCATTTCAT TGCATGGTCGTTAAGGCTT
hPAX9 GTTATGTTGCTGGACATGGGT GAAGCCGTGACAGAATGACTAC
Thekkeparambil Chandrabose et al. Stem Cell Research & Therapy  (2018) 9:68 Page 5 of 16
GSK3, and ROCK [32]. Colony formation on feeder
layers was observed in those supplemented with the
SMC4 cocktail as early as d13, while colony formation
was observed in the control (without SMC4) group only
at d18–22 (Additional file 1: Figure S2a). Under feeder-
free conditions, SMC4 addition accelerated colony for-
mation as early as d18 when compared with d22 in the
control group (Additional file 1: Figure S2a). Overall,
SMC4 addition improved the reprogramming efficiency
and colony formation in cells that were transfected with
episomal vectors using the nucleofection method in
feeder-free conditions. At d22–24, the colonies were
manually picked and passaged. Additional file 1: Figure
S3 shows the morphological changes in DPSCs during
reprogramming at different days post-reprogramming
using episomal vectors on feeder layers. SMC4 addition
strikingly resulted in not only early emergence of col-
onies, but also in a more compact iPS colony appearance
and increased number of colonies, indicative of higher
pluripotency and quality of the iPS colonies, as shown in
Additional file 1: Figure S2b and Table S2. Hence,
episomal-based DiPS generation was significantly im-
proved with SMC4 addition, especially in the feeder-free
condition, and thus was chosen for further studies. This
method also allowed us to pursue reprogramming using
animal source-free (xeno-free) generation of iPS
colonies, which would be more ideal for future clinical
applications.
Xeno-free and feeder-free episomal method for generating
DiPS cell lines
Since DPSCs undergo efficient reprogramming by
nucleofection with episomal vectors in the feeder-free
condition, we attempted to establish the xeno-free re-
programming protocol to generate clinical-grade iPS col-
onies. As depicted in the schematic time course in
Fig. 1a, DPSCs (n = 5) were cultured in xeno-free MSC
media and evaluated for their MSC characteristics by
flow cytometry. As shown in Additional file 1: Figure
S4a, b, DPSCs grown in xeno-free media exhibited
standard MSC characteristics in terms of morphology and
cell surface expression of the MSC markers (CD105+,
CD73+, CD90+, CD31−, CD14−, and CD45−).
The next day following transfection of the DPSCs
grown in xeno-free conditions with episomal vectors,
the cells were supplemented with sodium butyrate (0.5
mM). At d7, the media was changed to NutriStem
(xeno-free reprogramming/iPS media). Visible cell mor-
phological changes were observed from d9 to d10 from
fibroblast-like cells to more circular structures, later
forming a cluster and displaying the first emergence of
Fig. 1 Generation of clinically compatible DPSC-derived iPS cells using virus-free, xeno-free, and feeder-free approaches. a Schematic time course
of DiPS generation under xeno-free conditions and using small molecules. b Morphology of L1 DPSCs post-nucleofection under xeno-free and
feeder-free conditions at post-transduction days (d)7 (i), d13 (ii), and d17 (iii). c DiPS colonies expressing TRA-1-81 marker which were picked and
expanded for downstream characterisation. MSC mesenchymal stem cell
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iPS colonies (Fig. 1a). At d13, smaller colonies were
formed, and at d17 the colonies grew bigger, as shown in
Fig. 1a, b. Compared to the feeder-free reprogramming
method (Additional file 1: Figure S2a), this was signifi-
cantly much earlier, demonstrating the potency of the
xeno-free protocol. At d18, TRA-1-81-positive DiPS col-
onies (Fig. 1c) were counted and the reprogramming effi-
ciency was determined further by dividing by the number
of GFP-positive cells, estimated through flow cytometry
(Additional file 1: Figure S1c). Different DPSC lines from
young and adult humans were tested, with reprogram-
ming efficiencies ranging from 0.04% to 0.26% (mean =
0.16%, median = 0.19%; Table 2). Several clones from each
of all the DPSC lines were established and used for down-
stream analysis. All established DiPS lines displayed stand-
ard human ES-like morphology with a high nucleus to
cytoplasm ratio, more visible nucleoli, and with firmly
packed colonies (Fig. 1b). Collectively, our method estab-
lishes more convenient, robust, and improved xeno-free
and integration-free reprogramming protocol for DPSCs.
Characterisation of DiPS lines
To test the pluripotency of the xeno-free DiPS lines, live
cell immuno-staining was performed using standard
pluripotent markers such as TRA-1-60, TRA-1-81, and
alkaline phosphatase. The results indicated that the
DiPS cells showed expression of these markers
comparable to the H1 hES line which were also
maintained in xeno-free media (Fig. 2a). We also per-
formed cytogenetic analysis by karyotyping, and re-
sults revealed normal karyotypes in DiPS lines
(Fig. 2b and Additional file 1: Figure S5a).
Next, reverse-transcription qPCR analysis was per-
formed to show the mRNA expression of endogenous
pluripotency genes such as NANOG, OCT4, SOX2,
DPPA2, and LIN28, and endogenous somatic genes such
as ACTA, PDGFRA, TGFB1, and FN1 in all five DiPS
cell lines in comparison to their isogenic parental line
and H1. As expected, pluripotent genes were signifi-
cantly up-regulated and somatic genes were significantly
down-regulated in all DiPS lines (Fig. 2c) when com-
pared with their somatic cells of origin, further establish-
ing their pluripotency. Some variations in gene
expressions across cell lines were observed, consistent
with earlier reports that donor-specific heterogeneities
in the genetic and non-genetic background can
introduce such variability in iPS cells [33, 34].
For in vitro differentiation assays, embryoid bodies
(EBs) were generated from DiPS cells (Additional file 1:
Figure S5c) and, at day 7 onwards, the EBs were allowed
to differentiate spontaneously. The authenticity of differ-
entiation was assessed by three germ layer immunostain-
ing markers of EBs: ectodermal (beta-III tubulin
(TUJ1)), mesodermal (smooth muscle actin (SMA)), and
endodermal (alpha-fetoprotein (AFP)) markers, as shown
in Fig. 3a.
Concurrently, in vivo differentiation assay was per-
formed by examining teratoma formation in DiPS cell
lines that were injected into the subcutaneous area
above the thigh (quadriceps) muscle of immune-
compromised SCID mice. We confirmed the formation
of teratoma and identified the presence of structures
from all three germ layers, observed by H&E staining of
the teratoma section (Fig. 3d and Additional file 1:
Figure S5b).
Differentiation into neural progenitor cells
DPSCs have a neuro-ectoderm origin and are expected
to retain epigenetic memory of neuronal origins. The in-
herent potential of DiPS cells to differentiate towards
the neuronal lineage was demonstrated through forma-
tion of neural spheres and later towards neuronal pro-
genitor cells as shown in Fig. 3b. We used the H1 (ES)
cell line as a control along with L1 and AC_SHED iPS
lines to examine the effect of neuronal differentiation
potentials under xeno-free culture conditions. We
attempted neural progenitor formation using the DiPS
lines (L1 and AC_SHED) in comparison to H1 cells,
which were also maintained under the xeno-free culture
condition. The neural progenitor cells were immuno-
stained with the neural markers PAX6 and Nestin. As
shown in Fig. 3c, the DiPS lines generated using
xeno-free methods exhibited positive staining for
PAX6 and Nestin.
Genome-wide DNA methylation profiling of DiPS in
comparison to AiPS cells
To delineate epigenetic changes during reprogramming
of DPSCs, DiPS as well as AiPS cells derived from the
episomal-based reprogramming method were subjected
Table 2 Reprogramming efficiencies of DPSCs cultured under
xeno-free and feeder-free conditions
DPSC
sources
Transfection/
transduction efficiency
(GFP+ cells) (%)
No. of
TRA-1-81-positive
coloniesa
Reprogramming
efficiencyb (%)
L1 33.4 92.6 ± 5.1 0.13
L2 36.5 147 ± 12.03 0.20
AC_SHED 40.3 158 ± 15.5 0.19
AC_ADULT 22.2 115.6 ± 11.3 0.26
UM 19.1 18.66 ± 8.9 0.04
DPSC dental pulp stem cell, GFP green fluorescent protein
an = 3, mean ± SE
bReprogramming efficiency (%) = number of iPS colonies/number of
transduced or transfected cells
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Fig. 2 Pluripotent characterisation of clinically compatible DPSC-derived iPS cells using virus-free, xeno-free, and feeder-free approaches.
a Immunofluorescence results indicating that H1 hES and five DiPS cell lines express pluripotency markers TRA-1-60, TRA-1-81, and alkaline
phosphatase. b Karyotyping results of two representative DiPS lines. c Reverse transcription qPCR analysis results showing the expression levels of
pluripotency-related genes and mesenchymal genes of the H1 hES and DiPS cells relative to their isogeneic somatic cells. Note that H1 does not
have ‘somatic’ data
Thekkeparambil Chandrabose et al. Stem Cell Research & Therapy  (2018) 9:68 Page 8 of 16
to genome-wide DNA methylation analysis in compari-
son to their somatic origins and hES cells.
To compare DNA methylation levels between parental
somatic (DPSCs and ASCs) and iPS cells, with ES (H1
line) as a reference, unsupervised hierarchical clustering
of the methylation ratio (beta-values) was performed to
identify grouping of samples (Fig. 4a, b). The ES and iPS
(DiPS and AiPS) cells appeared indistinguishable from
each other and formed a tight cluster, well separated
from the other two clusters of the parental somatic cells,
DPSCs and ASCs (Fig. 4a, b). This result shows that the
DNA methylomes of iPS lines closely resemble those of
ES cells and yet are very distinct from their parental
DPSC/ASC lines. DNA methylation patterns of classical
pluripotent genes (SOX2, OCT4 (also known as
POU5F1), KLF4, C-MYC, LIN28, GLIS1), however, were
relatively unchanged in the whole cell samples, except
for NANOG (Fig. 4c).
Interestingly, DPSCs showed DNA methylation pro-
files closer to pluripotent cell (ES and iPS) populations
Fig. 3 Xeno-free DiPS cells can be spontaneously differentiated into all three germ layers under in vitro and in vivo conditions. a Three germ layer
immunostaining markers of EBs, ectoderm (beta-III tubulin (TUJ1)), mesoderm (smooth muscle actin (SMA)), and endoderm (alpha-fetoprotein (AFP)).
b DiPS-derived EBs differentiated to neural rosettes and further morphological changes of adherent neurospheres with cell extensions in xeno-free
media. (i) EBs generated from AC_SHED iPS cells in AggreWell™800 plates. (ii) On day 5, EBs were harvested and re-plated on matrix (poly-L-ornithine/
laminin)-coated culture plates. (iii) Neural rosette formation occurs from day 9–11. (iv) Neural rosettes formed were selected and re-plated on matrix
(poly-L-ornithine/laminin)-coated culture plates on day 12. (v) Attached neural rosette-containing clusters start forming neural progenitor cell
outgrowths. c Expression of neural markers Nestin and PAX6 by immunofluorescence for neural progenitor cells differentiated from xeno-free grown
DiPS and ES lines. d H&E staining of teratoma derived from AC_SHED iPS cells. The teratoma contains structures of all three germ layers (as shown by
the arrows)
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(Fig. 5a), compared with ASCs, in genes involved in de-
velopment, pluripotency, endoderm, mesoderm, and
ectomesenchyme. This explains the high efficiency of re-
programming of DPSCs when compared with ASCs
under the same culture conditions. Further delineation
of DNA methylation profiles led to identification of cer-
tain pluripotent and development-associated genes
(HERV-FRD, MGAT3, SPRY2, HOXB1, and PAX9) epit-
omizing the reprogramming dynamic of DPSCs (Fig. 5b,
c, Additional file 1: Table S3 and Table S4). These five
selected pluripotent-associated genes for DPSCs con-
tained regions of methylation levels on a par with iPS
cells (DiPS and AiPS) and H1 hES cells. In particular,
the gene locus of PAX9 in DPSCs shows a highly similar
epigenetic profile to the iPS/ES cells, especially at exons
4 and 5, which was not the case for ASCs. Other differ-
entially methylated genes of interest (> 80 genes) in
DPSCs versus ASCs in comparison with their respective
iPS and H1 ES cell lines are listed in Additional file 1:
Table S3. Additionally, results from IPA analysis demon-
strates the set of genes that undergo significant epigen-
etic changes when transforming from the somatic cell
state (DPSCs/ASCs) into the iPS (DiPS/AiPS) cell state
as depicted in Additional file 1: Table S5. Notable
Fig. 4 DNA methylation profiling of DiPS and AiPS cell lines in comparison to their parental cells. a Heatmap of the methylation ratio (beta-value)
of global probe sets for genes in the dental-derived somatic parental (L1, UM), DiPS (L1 iPS, UM iPS), and H1 ES cells. Duplicates for each cell line.
b Heatmap of the methylation ratio (beta-value) of global probe sets for genes in the adipose-derived somatic parental (PC, SP, L), AiPS (PC iPS,
SP iPS, L iPS), and H1 hES cells. Duplicates for each cell line. c Heatmap representing classic pluripotent genes in parental DPSCs and ASCs with
respect to their resultant iPS lines and H1 hES cells. The methylation ratio is averaged across all probes for each gene and across all samples in
the same group. AiPS adipose-derived stem cell-derived induced pluripotent stem, ASC adipose-derived stem cell, DiPS dental pulp stem
cell-derived induced pluripotent stem, DPSC dental pulp stem cell, ES embryonic stem, iPS induced pluripotent stem
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epigenetic changes were undertaken in ASCs in com-
parison with DPSCs after reprogramming into iPS cells,
unravelling the significance of the starting cell popula-
tion for iPS generation. We found that among the top
enriched networks of the genes in IPA, analysis includes
“cellular development, cellular growth and proliferation,
connective tissue development and function,” and “gene
expression, cell morphology, cellular assembly, and
Fig. 5 Proximity of DNA methylation markers in DPSCs to hES and iPS cells. a Heatmap of the methylation ratio of probes for selected genes involved
in pluripotency, development, endoderm, mesoderm, and ectomesenchyme in the dental- and adipose-derived somatic parental cell lines, DiPS, AiPS,
and ES cells. Duplicates for each cell line. b Methylation levels of five selected developmentally associated genes for dental- and adipose-derived
somatic cells with respect to iPS cells (DiPS and AiPS) and H1 hES. The probe sets for each gene analysed are: HER-FRD = cg25106036; HER-FRD =
cg214999175; HOXB1 = cg24948406; MGAT3 = cg00101350; SPRY2 = cg00185066. See Additional file 1 (Table S3) for original data. c Gene model of
PAX9 showing methylation levels (black being completely methylated and white completely unmethylated) at different probe sets. DPSCs show a
highly similar epigenetic profile to ES and iPS cells at exons 4 and 5, but not ASCs. See Additional file 1: Table S4 for original probe sets data. AiPS
adipose-derived stem cell-derived induced pluripotent stem, ASC adipose-derived stem cell, DiPS dental pulp stem cell-derived induced pluripotent
stem, DPSC dental pulp stem cell, ES embryonic stem, iPS induced pluripotent stem
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organisation.” Altogether our results indicate that DPSCs
exhibit epigenetic signatures of many developmental
genes that are closer to those of pluripotent stem cells,
at least partially accounting for their favourable repro-
gramming capability.
Overexpression of PAX9 and knockdown HERV-FRD improve
reprogramming
Among the differentially methylated genes, we picked
PAX9 and HERV-FRD to further investigate their roles
in reprogramming. As shown in Fig. 5c, PAX9 contains
various regions in DPSCs that are hypomethylated com-
pared with ASCs and that are similar to those in iPS/ES
cells. In contrast, HERV-FRD includes at least two
hypermethylated sites in DPSCs that are similar to those
in iPS/ES cells, which is hypomethylated in ASCs
(Fig. 5b). We transiently over-expressed PAX9 and
knocked-down HERV-FRD in DPSCs, and examined
their effects on reprogramming. As expected, after indu-
cing the over-expression (OE) of PAX9 and knock-down
(KD) of HERV-FRD, the transcript level of PAX9 was
up-regulated while that of HERV-FRD was down-
regulated (Fig. 6a). Furthermore, the iPS colonies that
were generated from these PAX9 OE and HERV-FRD
KD cell lines and their reprogramming efficiency was
assessed in the presence and absence of SMC4 (Fig. 6b,
c). Both PAX9 OE and HERV-FRD KD cell lines exhib-
ited increased iPS colony number compared with mock
transfected control cells (Fig. 6d).
Presence of DPSC subpopulation that exhibits more
pluripotent and self-renewal supporting capacities
Our epigenetic study indicates that DPSCs already have
higher pluripotent potential than ASCs, even without re-
programming factors. During DPSC culture we noted
the occurrence of a peculiar scanty clonal structure
within the normal fibroblast-like DPSCs. Due to its re-
semblance to a compact iPS/ES colony-like structure, we
performed standard pluripotent cell live staining using
TRA-1-60, SSEA-3, and Connexin-43 on normal DPSC
culture. Connexin-43, a gap junction protein, is also sig-
nificantly involved in embryonic development [35]. Its
Fig. 6 Effects of PAX9 and HERV-FRD modulations in iPS reprogramming. a Reverse transcription qPCR analysis results showing the over-expression
(OE) levels of PAX9 and knock-down (KD) level of HERV-FRD genes in the DPSC (L1) line. b Immunofluorescence results of TRA-1-60 expression for iPS
clones generated without SMC4 cocktail in control, PAX9 over-expressing, and HERV-FRD knock-down DPSC (L1) lines. c Immunofluorescence results
of TRA-1-60 expression for iPS clones generated with SMC4 cocktail in control, PAX9 over-expressing, and HERV-FRD knock-down DPSC (L1) lines.
d Number of iPS colonies counted from control, PAX9 over-expressing, and HERV-FRD knock-down DPSC (L1) lines reprogrammed with and without
SMC4 cocktail
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involvement in the course of reprogramming is also
reported through regulation of E-cadherin, which later
mediates mesenchymal-to-epithelial transition (MET)
[35, 36]. To our surprise, these DPSC-derived satellite-like
structures sporadically displayed pluripotent surface marker
expressions for TRA-1-60, SSEA-3, and Connexin-43,
which may account for the higher propensity of DPSCs for
iPS generation (Additional file 1: Figure S6a).
In addition, it was previously demonstrated that
feeder-free reprogramming is possible with ASCs since
ASCs themselves possess an ability to support self-
renewal of other pluripotent stem cells [9]. We thus
evaluated the suitability of DPSCs as a feeder layer in
comparison with ASCs and MEF to support pluripo-
tency of H1 hES cells, and found that DPSCs also have a
comparable capacity as feeders (Additional file 1: Figure
S6b). In our study, both DPSC- and ASC-derived feeder
layers supported the H1 cell maintenance. However, a
certain degree of variation in expression of pluripotent
genes was observed. H1 cells supported by ASCs exhib-
ited higher SSEA4 expression than those supported by
DPSC feeder layers. On the other hand, DPSCs were
slightly superior in terms of supporting TRA-1-81 and
TRA-1-60 expression in H1 cells compared with MEF
and ASC feeder layers (Additional file 1: Figure S6b).
Therefore, even though all three feeder layers seem to be
more or less supportive of H1 cell self-renewal, DPSCs
may maintain expression of authentic pluripotent
markers such as TRA-1-81 and TRA-1-60 better than
ASCs and even MEF. Our observation indicates the po-
tential of DPSCs as human-derived cell feeders as well
as the cell source for iPS reprogramming, which further
justifies their suitability for clinical use.
Discussion
Although iPS cells can be routinely generated for many
purposes, there is still no consent on the best repro-
gramming method for clinical applications as this may
be highly affected by pre-disposed cellular factors in-
cluding their maturity, complexity, and origin. This vari-
ance in reprogramming efficiencies is apparent when
different cell populations from different tissues are used
[6, 12]. In our findings, human DPSCs can be easily re-
programmed into iPS cells with the conventional viral
approach. Importantly, the same efficacy was consist-
ently obtained with the episomal mode of reprogram-
ming for DPSCs, which has the advantage of clinical
safety by avoiding potential viral gene integration into the
cells. In a clinical perspective, standard operation proce-
dures using iPS cells would highly favour those that in-
volve manageable tissue sources, with minimal patient
discomfort during harvesting, ideally from low-cost bio-
logical waste, short-time frame, and minimal processing
cost and complications. DPSCs are advantageous in these
aspects. The presence of certain cellular signalling factors
may play a significant role in the favourable fate determin-
ant of DPSCs. Families of such factors may include Wnt,
Notch, and BMP, which are known to regulate the fate of
cells by mediating the molecular cross-talk [37]. Notably,
the TGF-β/activin pathway was reported to maintain the
pluripotent state, whereas the p53 pathway acts as a bar-
rier for cell reprogramming [38]. Interestingly, the positive
reprogramming process of DPSCs can be at least partially
explained by its reduced level of p53 molecules accom-
panied by abundant expression of all the members of
TGF-β signalling molecules [21]. In addition, we found
that at least some populations of DPSCs have high intrin-
sic expression for pluripotent markers such as SSEA3,
Tra-1-60, and Connexin-43, which suggests a lower bar-
rier to undergoing reprogramming into pluripotency.
With the conventional method it takes approximately
30 days to derive human iPS cells with a reprogramming
success rate of approximately 0.01% using fibroblasts, as
reported earlier [1]. The reprogramming rate has been
progressively improved using different cell lines and
implementing various modes of vector systems. For in-
stance, the rate was improved to 0.2% or higher using
ASCs [22, 31]. Later, and with the advent of more clinic-
ally acceptable methods such as integration-free epi-
somal plasmids, human iPS generation efficiency was
further improved by 0.5% as reported in human gingival
tissue [39]. However, the reprogramming procedure may
still take as long as for fibroblasts, and may not be ro-
bustly reproducible under clinically compatible condi-
tions. In this paper, we made efforts to further improve
the clinically applicable reprogramming protocol by suc-
cessfully generating virus-free DiPS cells using episomal
plasmids in a more refined manner using a small mol-
ecule cocktail of four inhibitors (SMC4 cocktail) and
under the xeno-free culture condition. This protocol
was relatively quick (less than 18 days in colony forma-
tion), handy, reproducible, and capable of inducing
feeder-free pluripotency of primary DPSCs from five dif-
ferent donors. All the five DiPS lines generated in our la-
boratory had standard pluripotent characteristics
equivalent to ES cells, which include the expression of
pluripotent surface markers using immunostaining and
reverse-transcription qPCR, spontaneous in vitro differ-
entiation, and in vivo differentiation potential through
teratoma formation and karyotyping analysis. Unexpect-
edly the reprogramming efficiency of DPSCs using epi-
somal vectors under feeder-free and xeno-free conditions
were higher (0.19%) than the conventional viral methods
using feeder-free layers (0.05%), thereby generating higher
numbers of iPS clones. This is possibly because of the sto-
chastic mode of reprogramming as previously suggested
by Yamanaka [40], where cells could be reprogrammed in
the right direction only with the right amount and balance
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of different reprogramming factor expressions. This subtle
balance may be influenced by the mode of transfection af-
fecting expression of the reprogramming transgenes [41].
In addition, DPSCs were found to exhibit a higher
feeder-free reprogramming capability. The feeder inde-
pendence of human cell sources was previously noted
for ASCs because this cell type can support self-renewal
of other pluripotent stem cells when used as a feeder
layer [22]. We showed that DPSCs exhibit comparable
or even higher feeder-free reprogramming efficiency and
support pluripotency of human ES cells when DPSCs
themselves were used as feeders. This indicates the po-
tential clinical use of DPSCs as an alternative human-
derived feeder source. Furthermore, we optimised the
episomal-based xeno-free protocol for DiPS generation
and showed that DiPS cells can be derived in less than 14
days. This was achieved by adopting a cocktail complex of
SMC4 consisting of SB431542 (TGFβi), PD0325901
(MEKi), CHIR99021 (GSK3i), and Thiazovivin (ROCKi),
which was shown to improve reprogramming efficiency as
described by Valamehr et al. [42]. Combination of these
four small molecules resulted in high cell viability, sur-
vival, high clonality (colony compactness), and enrichment
of homogeneous iPS clones from reprogrammed DPSCs.
Thus, we believe that the use of SMC4 is highly suitable
for industrial and clinical applications.
Although DPSCs exhibit a higher capability to become
iPS cells, very little has been studied regarding their epigen-
etic basis. In our studies, we investigated epigenetic mecha-
nisms of the favourable reprogramming propensity of
DPSCs. Our global DNA methylation analysis indicates that
DPSCs, which express considerable levels of pluripotency-
associated factors even without reprogramming, also ex-
hibit various methylation marks predisposed for pluripo-
tency compared with ASCs. The candidate genes HERV-
FRD, SPRY2, and MGAT3 were highly methylated and
PAX9 and HOXB1 relatively unmethylated in DPSCs, levels
similar to ES and iPS cells as shown in Fig. 5. For instance,
the paired box 9 (PAX9) homeobox gene is well known for
its critical role during development in orchestrating growth
factors, developmental cytokines, adhesion molecules, and
its complex interactions in embryonic- as well as neural
crest-derived tissues [43, 44]. HERV-W, also known as
Syncytin-1 and an isoform of HERV-FRD, was reported to
be a specific marker of the human trophoblast [45]. A very
recent report confirmed the expression of Syncytin-1 to be
mainly associated with trophoblast cells of the blastocyst
particularly in cells underlying the inner cell mass [46].
Interestingly, Syncytin-1 was previously identified in mem-
brane proteins involved directly in trophoblastic cell adhe-
sion molecules along with Connexin-43 and ZO-1 [47, 48].
This may be in accordance with our experimental observa-
tion of Connexin-43 expression during DPSC culture. In
contrast, the role of HERV-FRD/Syncytin-2 is enigmatic,
but one piece of evidence suggests that it is also expressed
in human trophoblasts and plays an important role in
trophoblast cell fusion [49]. Based on the DNA methylation
results, we selected PAX9 and HERV-FRD genes due to the
presence of multiple differentially methylated regions that
are equivalent to iPS/ES cells and examined their effects.
Accordingly, PAX9 was over-expressed (PAX9-OE) and
HERV-FRD was knocked-down (HERV-FRD-KD) in
DPSCs for evaluation of the reprogramming propensity.
Consistent with expectation, increases in generation of iPS
colonies were observed in both cell lines, indicating that
PAX9 serves as an enhancing factor and HERV-FRD as a
suppressing factor for iPS reprogramming. An important
question remaining to be answered is how the developmen-
tal PAX9 and HERV-FRD genes regulate the reprogram-
ming process, and this warrants additional study. Although
the prime determinants and effects of epigenetic changes
during induced pluripotency are not fully understood, it is
clearly perceived that dynamic changes in epigenetic signa-
tures from the somatic state into the pluripotent state are
needed to acquire pluripotency [50]. Our results indicate
that DPSCs are advantageous since the cells already possess
certain degrees of epigenetic marker similarity to the iPS
state, especially regarding developmental genes presumed
to play important roles in regulating pluripotency.
The use of DPSCs as a source for iPS cells may have
additional advantages for cell replacement therapy or
modelling disease physiology because of their epigenetic
inclination toward certain cell lineage. For example,
DPSCs are in the neural crest origin and thus can be
more inclined towards differentiation to the neural cell
types [51]. We hypothesise that epigenetic memory of
the neural crest origin may remain and successfully dif-
ferentiate DiPS cells, but not AiPS cells, to neural
progenitor-like cells in vitro. Future work is necessary to
develop further directed differentiation protocols to de-
rive DiPS cells into various functional cell types. In
addition, while the xeno-free reprogramming protocol
was established in this paper, development of a suitable
xeno-free isolation and initial culture of DPSCs may still
be necessary for optimal clinical applications. Collect-
ively, the epigenetic advantage of DPSCs as the starting
cell material for generating fast, efficient, and high-
quality iPS cells and their differentiated cells can be fully
utilised in regenerative medicine if further advances in
clinically compatible protocols are made.
Conclusion
To develop safe and efficient iPS generation methods to-
wards clinical applications, we established non-integrative
episomal-based reprogramming of DPSCs in the feeder-
free and xeno-free culture condition. Importantly, this
xeno-free episomal method can more efficiently repro-
gramme DPSCs compared with the conventional viral
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method. Further refinement of this procedure by including
the SMC4 cocktail resulted in both a shorter time (< 14
days) and higher quality of the reprogramming process.
DPSCs may be more pre-disposed to feeder/xeno-free
reprogramming because they express relatively high levels
of pluripotent markers and can serve themselves as a
feeder layer for human pluripotent stem cells. In addition,
DPSCs exhibit epigenetic DNA methylation marks of cer-
tain development-associated genes in relative proximity to
those of human ES and iPS cells. Among these genes, it
was found that PAX9 would enhance and HERV-FRD/
Syncytin-2 repress reprogramming into iPS cells. These
combined properties of DPSCs may make them amenable
for iPS cell research and subsequent clinical applications.
Further work is necessary for more in-depth understand-
ing of the molecular regulatory mechanisms of DPSC re-
programming and the development of DiPS-based novel
therapies in the regenerative arena.
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